

Date: 07th August 2020
Bengaluru

**M/S Bombay stock Exchange of India
Corporate Services
P.J. Towers
Mumbai-400001**

Security Code: 524654

Sir/ Madam,

Sub: Outcome of Board Meeting held on 07th August, 2020

Board of Directors at their meeting held on 07.08.20, inter alia has transacted the following:

1. Adoption of Standalone & Consolidated Unaudited Financial Results for the quarter Ended 30th June 2020.

Further in compliance with Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we submit herewith, the unaudited standalone and consolidated financial results along Limited Review report for the First quarter ended 30th June, 2020.

We shall arrange to publish the unaudited financial results in the newspapers.

2. The Company disinvested its investment in Supreme Pharmaceuticals Mysore Private Limited for Rs. 7.25 cr. The profit for the disinvestment of Rs. 2.17 cr. has been considered in the quarterly results.

3. The proposed transaction to acquire API business of Naari Pharma Private Limited has been mutually terminated, due to delay in various approvals for the transaction.

The meeting commenced at 03.00 PM and concluded at 6.00 PM.

Kindly take the above information on records.

Thank You,

For Natural Capsules Limited


**Sunil L Mundra
Managing Director**

P. CHANDRASEKAR LLP

Chartered Accountants

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
CONSOLIDATED FINANCIAL RESULTS.**

TO

The Board of Directors,
Natural Capsules Limited
Bangalore

1. We have received the accompanying statement of Consolidated unaudited financial results of **M/s. NATURAL CAPSULES LIMITED** (the Parent) and its subsidiaries (the Parent and its subsidiaries together referred to as the Group), for the quarter ended June 2020 ("the Statement"), which are included in the accompanying statement of consolidated unaudited Financial results. This statement has been prepared by the company pursuant to the requirement of Regulation 33 of the securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as modified by circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This statement is the responsibility of the company's Management and has been approved by the Board of Directors. This Statement has been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 and other accounting principles generally accepted in India. Our Responsibility is to issue a report on the statement of consolidated unaudited financial results based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Bangalore * Chennai

4. We did not review the interim financial results of one subsidiary included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. Nil for the quarter ended 30 June 2020, total net profit after tax of Rs. Nil for the quarter ended 30 June 2020 as considered in the Statement. These interim financial results have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports furnished by the management. In our opinion and according to the Information and explanations given to us by management, these financial statements and other financial information are not material to the Group. Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the financial information certified by management.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of consolidated unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard as specified under section 133 of the Companies Act 2013 read with relevant rules issued thereunder other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular number CIR/CFD/FAC/62/2016 dated July 5 2016 including the manner in which it is to be disclosed , or that it contains any material misstatement.

UDIN: 20026037 AAAADU 8947

For P. Chandrasekar LLP
Chartered Accountants
FRN No: 000580S/S200006



P. Chandrasekaran
Partner
Membership No: 026037

Date: August 7th, 2020



NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23, 100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011

Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE, 2020

Rs. in Lacs

Sl. No.	PARTICULARS	Quarter Ended			Year Ended	
		30th June 2020	30th June 2019	31st March, 2020	31st March 2020	
		Unaudited	Unaudited	Audited	Audited	
1	Revenue from operations	1,600	1,402	1,565	6,155	
2	Other Income	34	27	21	95	
3	Total Income (1+2)	1,634	1,429	1,586	6,251	
4	Expenses					
	a) Cost of Material consumed	749	688	609	2,792	
	b) Purchase of stock-in-trade	(8)	(98)	-	-	
	c) (Increase) / Decrease in stock in trade	182	167	73	11	
	d) Employees benefits expense	15	15	177	699	
	f) Finance cost	103	90	19	77	
	g) Depreciation	517	522	132	412	
	h) Other Expenses			555	2,123	
	Total Expenses	1,558	1,384	1,565	6,114	
5	Profit from ordinary activities after finance costs but before exceptional items	76	45	21	137	
6	Exceptional Items Income /(Expenses)	218	-	-	-	
7	Profit from ordinary activities before tax	294	45	21	137	
8	Tax Expense					
	- Current Tax	46	10	10	51	
	- Income tax (Prior year)	60	23	3	66	
	- Deferred Tax	-	-	-	-	
		(15)	(13)	7	(14)	
9	Net Profit (+) / Loss (-) from ordinary activities after tax	248	35	11	86	
10	Other Comprehensive income (OCI)					
	a) Items that will not be reclassified to profit or loss (net of tax)	-	-	2	2	
	b) Items that will be reclassified to profit or loss (net of tax)	-	-	-	-	
11	Total Comprehensive Income (OCI) for the period	248	35	13	88	
12	Paid-Up Equity Share Capital (face value per share Rs.10/-)	623	623	623	623	
13	Earnings Per Share of (before & after extraordinary items) Rs. 10/-					
	(a) Basic	3.98	0.57	0.22	1.41	
	(b) Diluted	3.98	0.57	0.22	1.41	




Note:

- 1 The unaudited Consolidated financial results of the Company for the Quarter Ended 30th June 2020 have been approved by the Board of Directors of the Company at its meeting held on 7th August, 2020. The figures for the Quarter ended 30th June 2020 was subject to 'Limited Review' by Statutory Auditors of the Company who have expressed an unqualified review opinion.
- 2 The Unaudited Consolidated Financial results for the Quarter Ended 30th June 2020 have been prepared above in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above Unaudited Standalone Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.
- 3 Previous years figures have been regrouped wherever necessary.
- 4 The figures for the quarter ended March 2020 are arrived at as difference between audited figures in respect of full financial year for the year ended March 31 2020 and the reviewed figures upto nine months period ended December 31st 2019
- 5 Exception Items is profit earned on sale of shares Invested in Supreme Pharmaceuticals Mysore Private Limited during the quarter.
- 6 Position of investor complaints for the quarter ended 30th June 2020

Particulars	
Pending as on 01-04-2020	Nil
Received during the quarter	Nil
Resolved during the quarter	Nil
Pending as on 30-06-2020	Nil

Place : Bangalore

Date : 7th August 2020



P. CHANDRASEKAR LLP

Chartered Accountants

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS.

TO

The Board of Directors,
Natural Capsules Limited,
Bangalore.

1. We have received the accompanying statement of unaudited financial results of **M/s. NATURAL CAPSULES LIMITED** ("the company") for the quarter ended June 2020 ("the Statement"), which are included in the accompanying statement of unaudited Financial results. This statement has been prepared by the company pursuant to the requirement of Regulation 33 of the securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as modified by circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This statement is the responsibility of the company's Management and has been approved by the Board of Directors. This Statement has been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 and other accounting principles generally accepted in India. Our Responsibility is to issue a report on the statement of unaudited financial results based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Bangalore * Chennai

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard as specified under section 133 of the Companies Act 2013 read with relevant rules issued thereunder other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular number CIR/CFD/FAC/62/2016 dated July 5 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2020 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit

UDIN: 26026037AAADT3720

For P. Chandrasekar LLP
Chartered Accountants
FRN No: 000580S/S200006



P. Chandrasekaran
Partner
Membership No: 026037



Date: August 7th, 2020

NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011

Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE, 2020

Rs. in Lacs

Sl. No.	PARTICULARS	Quarter Ended		Year Ended	
		30th June 2020	30th June 2019	31st March, 2020	31st March 2020
		Unaudited	Unaudited	Audited	Audited
1	Revenue from operations	1,600	1,402	1,565	6,155
2	Other Income	34	27	21	95
3	Total Income (1+2)	1,634	1,429	1,586	6,251
4	Expenses				
	a) Cost of Material consumed	749	688	609	2,792
	b) Purchase of stock-in-trade	(8)	(98)	-	-
	c) (Increase) / Decrease in stock in trade	182	167	177	11
	d) Employees benefits expense	15	15	19	699
	f) Finance cost	103	90	132	77
	g) Depreciation	517	522	555	412
	h) Other Expenses				2,123
	Total Expenses	1,558	1,384	1,565	6,114
5	Profit from ordinary activities after finance costs but before exceptional items	76	45	21	137
6	Exceptional Items Income / (Expenses)	218	-	-	-
7	Profit from ordinary activities before tax	294	45	21	137
8	Tax Expense				
	- Current Tax	46	10	10	51
	- Income tax (Prior year)	60	23	3	66
	- Deferred Tax	-	-	-	-
		(15)	(13)	7	(14)
9	Net Profit (+) / Loss (-) from ordinary activities after tax	248	35	11	86
10	Other Comprehensive income (OCI)				
	a) Items that will not be reclassified to profit or loss (net of tax)	-	-	2	2
	b) Items that will be reclassified to profit or loss (net of tax)	-	-	-	-
11	Total Comprehensive Income (OCI) for the period	248	35	13	88
12	Paid-Up Equity Share Capital (face value per share Rs.10/-)	623	623	623	623
13	Earnings Per Share of (before & after extraordinary items) Rs. 10/-				
	(a) Basic	3.97	0.57	0.22	1.41
	(b) Diluted	3.97	0.57	0.22	1.41

Note:

- 1 The audited standalone financial results of the Company for the Quarter Ended 30th June 2020 have been approved by the Board of Directors of the Company at its meeting held on 7th August, 2020. The figures for the Quarter ended 30th June 2020 was subject to 'Limited Review' by Statutory Auditors of the Company who have expressed an unqualified review opinion.
- 2 The Unaudited Standalone Financial results for the Quarter Ended 30th June 2020 have been prepared above in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above Unaudited Standalone Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.
- 3 Previous years figures have been regrouped wherever necessary.
- 4 The figures for the quarter ended March 2020 are arrived at as difference between audited figures in respect of full financial year for the year ended March 31 2020 and the reviewed figures upto nine months period ended December 31st 2019
- 5 Exception Items is profit earned on sale of shares Invested in Supreme Pharmaceuticals Mysore Private Limited during the quarter.
- 6 Position of investor complaints for the quarter ended 30th June 2020

Particulars	
Pending as on 31-03-2020	Nil
Received during the quarter	Nil
Resolved during the quarter	Nil
Pending as on 30-06-2020	Nil

Place : Bangalore

Date : 7th August 2020

